Company: BNBX
Filing Date: 2025-04-04
Form Type: PRE 14A
Source: 0001104659-25-032262
Chunk: 16

Company: BNB PLUS CORP.
Filing Date: 2025-04-04
Form: PRE 14A
Chunk 16
---
 Directors. The Company intends that the proxy in the form presented will be voted, unless otherwise indicated, for the election of these nominees to serve until the 2025 Annual Meeting of Stockholders, or until their successors are elected and qualified. Our Certificate of Incorporation provides that the number of directors that constitute the whole Board of Directors shall be fixed exclusively in the manner designated in the Company’s Bylaws. The Company’s Bylaws provide that the number of directors is determined by resolution of the Board of Directors, provided that the Board of Directors shall consist of at least one member. As of the Annual Meeting, the number of directors shall be fixed at six. Should one or more of these nominees be unable to accept nomination or election as a director, the individuals named as proxy holders, Ms. Beth Jantzen and Ms. Judith Murrah, will vote the shares that they represent for such other persons as the Board of Directors may recommend. The Board of Directors has no present knowledge that any of the nominees for director named below will be unavailable to serve. The directors standing for re-election, together with their ages as of April 3, 2025, and certain other information, are:

8

TABLE OF CONTENTS

| Director          | ​ | ​ | Age | ​ | ​ | YearFirstBecameDirector | ​ | ​ | Principal Occupation and Other Board ofDirectors Service During the Past Five Years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ​ |
| ​                 | ​ | ​ |   ​ | ​ | ​ |                       ​ | ​ | ​ | on the boards of NeoMatrix Formulations, Inc. and the TNPO2 Foundation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | ​ |
| ​                 | ​ | ​ |   ​ | ​ | ​ |                       ​ | ​ | ​ | Dr. Hayward’s experience and senior leadership positions in companies in the biotechnology, pharmaceutical and consumer-product industries, and specifically his qualifications and skills in the areas of general operations, financial operations and administration, as well as his role as the Company’s Chief Executive Officer, led the Board of Directors to conclude that Dr. Hayward should serve as a director of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ​ |
| Robert B. Catell  | ​ | ​ |  88 | ​ | ​ |                    2016 | ​ | ​ | Robert B. Catell has been a member of the Board of Directors since October 7, 2016. Mr. Catell serves as